However, miR-34a had only a minor affect in decreasing ATG4B expression, suggesting that unlike CML cells [50], ATG4B is not likely a target of miR-34a in prostate cancer cells. This evidence concerns the gene ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive.